The second bellwether trial against Sanofi-Aventis over its prescription chemotherapy drug Taxotere began today.

The trial in New Orleans is one of nearly 12,500 lawsuits coordinated in multidistrict litigation alleging that women who take Taxotere, a chemotherapy drug used to treat breast cancer, never grow back their hair, a side effect the U.S. Food and Drug Administration acknowledged in a labeling change in 2015. The first bellwether trial ended in a defense verdict in 2019.

The plaintiff, Elizabeth Kahn, 63, a school librarian who lives in New Orleans, alleges Sanofi-Aventis failed to warn about Taxotere's risk of permanent hair loss. She began treatment for breast cancer in 2008, including four cycles of Taxotere as well as radiation and hormone therapy treatment and a lumpectomy.